Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.

Rupert Bartsch, Catharina De Vries, Ursula Pluschnig, Peter Dubsky, Zsuzsanna Bago-Horvath, Simon Peter Gampenrieder (Co-author), Margaretha Rudas, Robert M Mader, Andrea Rottenfusser, Christoph Wiltschke, Michael Gnant, Christoph C Zielinski, Guenther G Steger

    Research output: Contribution to journalOriginal Articlepeer-review

    19 Citations (Web of Science)
    Original languageEnglish
    Pages (from-to)367
    JournalBMC CANCER
    Volume9
    DOIs
    Publication statusPublished - 2009

    Keywords

    • METASTATIC BREAST
    • MONOCLONAL-ANTIBODY
    • PHASE-II
    • SAFETY
    • EFFICACY
    • DISEASE
    • CAPECITABINE
    • CHEMOTHERAPY
    • PROGRESSION
    • RECEPTORS

    Cite this